Myristoleic acid is a tedecaenoic acid with double bonds at positions 9-10 and a Z configuration. Myristoleic acid, a cytotoxic component of Serenoa repens extract, can induce apoptosis and necrosis of human prostatic cells.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Yong-Guy Kim, et al. Phytomedicine. Antibiofilm activities of fatty acids including myristoleic acid against Cutibacterium acnes via reduced cell hydrophobicity
 Youn Kyung Choi, et al. Biomol Ther (Seoul). Myristoleic Acid Promotes Anagen Signaling by Autophagy through Activating Wnt/β-Catenin and ERK Pathways in Dermal Papilla Cells
 Lin-Hu Quan, et al. Gut. Myristoleic acid produced by enterococci reduces obesity through brown adipose tissue activation
 Jun-Oh Kwon, et al. Eur J Pharmacol. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2
 K Iguchi, et al. Prostate. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells
|Related Apoptosis Products|
Misetionamide is an orally glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor with antineoplastic activity.
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models.
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.